Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Financing Activities (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Cash from Financing Activities data on record, last reported at -$208000.0 in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 289.09% year-over-year to -$208000.0; the TTM value through Dec 2025 reached $257.0 million, up 73758.91%, while the annual FY2025 figure was $257.0 million, 73758.91% up from the prior year.
  • Cash from Financing Activities reached -$208000.0 in Q4 2025 per AMLX's latest filing, down from $191.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $232.2 million in Q4 2022 and bottomed at -$1.1 million in Q4 2021.
  • Average Cash from Financing Activities over 5 years is $44.8 million, with a median of $889000.0 recorded in 2023.
  • The widest YoY moves for Cash from Financing Activities: up 239407.5% in 2025, down 289.09% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$1.1 million in 2021, then skyrocketed by 21899.25% to $232.2 million in 2022, then tumbled by 99.9% to $230000.0 in 2023, then crashed by 52.17% to $110000.0 in 2024, then plummeted by 289.09% to -$208000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$208000.0 in Q4 2025, $191.6 million in Q3 2025, and -$31000.0 in Q2 2025.